Emerging Therapies in DMD

This episode surveys the DMD clinical trial landscape, with Dr. Chrzanowski leading the discussion on the most compelling emerging therapies. He opens by acknowledging the surge in trial activity, expressing cautious optimism about what the pipeline holds for families.

Next-generation microdystrophin gene therapies are highlighted as "second-generation" approaches that refine vector design, transgene composition, promoters, and tissue targeting. It remains too early to determine which will prove superior, but the panel is enthusiastic.

Two mutation-agnostic muscle-targeted therapies are discussed in depth. The first is domagrozumab (a cardiomyopathy-focused nanosphere therapy), aimed at improving cardiac function and upper extremity function in non-ambulatory patients via quarterly infusions. The second is sevasemten, which targets fast-twitch myosin isoforms. Since fast-twitch fibers sustain preferential injury in DMD, this agent aims to shift the muscle's composition toward the slower, more protected slow-twitch variety—applicable not just in DMD but in myopathies broadly.

Second-generation exon skipping therapies are also reviewed. These newer chemistries offer extended half-lives, improved efficacy, cardiac targeting, and potential CNS penetration. The shift from weekly infusions to dosing every six weeks represents a meaningful quality-of-life improvement. The panel also raises the potential for platform exon-skipping trials capable of addressing a broader range of mutations, with estimates suggesting 80–90% of patients may be exon-skipping amenable.

In the next episode, " Unmet Needs and Emerging Horizons for DMD," Dr. Brenda Wong, Chief Medical Advisor at Cure Duchenne, discusses how advocacy organizations support families across the full DMD disease journey.